|Day's Range||62.00 - 62.00|
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 million SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE
Thermo Fisher Scientific (TMO) closed at $555.19 in the latest trading session, marking a +0.16% move from the prior day.
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.